Literature DB >> 11070045

CD4 T-cell responses to herpes simplex virus type 2 major capsid protein VP5: comparison with responses to tegument and envelope glycoproteins.

D M Koelle1, M Schomogyi, C McClurkan, S N Reymond, H B Chen.   

Abstract

We used CD4 lymphocyte clones from herpes simplex virus type 2 (HSV-2) lesions or the cervix and molecular libraries of HSV-2 DNA to define HSV-2 major capsid protein VP5 and glycoprotein E (gE) as T-cell antigens. Responses to eight HSV-2 glycoprotein, tegument, nonstructural, or capsid antigens were compared in 19 donors. Recognition of VP5 and tegument VP22 were similar to that of gB2 and gD2, currently under study as vaccines. These prevalence data suggest that HSV capsid and tegument proteins may also be candidate vaccine antigens.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11070045      PMCID： PMC113250          DOI： 10.1128/jvi.74.23.11422-11425.2000

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  40 in total

1.  Significance of local gamma interferon in recurrent herpes simplex infection.

Authors:  J W Torseth; T C Merigan
Journal:  J Infect Dis       Date:  1986-05       Impact factor: 5.226

2.  Lymphocyte and IgG responses to different herpes simplex virus antigens in patients with frequent HSV-1 reactivations.

Authors:  P Ljungman; L Zetterqvist; V A Sundqvist; S Jeansson; A Heimdahl; B Wahren
Journal:  Clin Exp Immunol       Date:  1988-05       Impact factor: 4.330

3.  Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. IV. Recognition and activation by cloned glycoproteins gB and gD.

Authors:  J M Zarling; P A Moran; R L Burke; C Pachl; P W Berman; L A Lasky
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

4.  Baculovirus-expressed glycoprotein E (gE) of herpes simplex virus type-1 (HSV-1) protects mice against lethal intraperitoneal and lethal ocular HSV-1 challenge.

Authors:  H Ghiasi; R Kaiwar; A B Nesburn; S Slanina; S L Wechsler
Journal:  Virology       Date:  1992-06       Impact factor: 3.616

5.  pUEX, a bacterial expression vector related to pEX with universal host specificity.

Authors:  G M Bressan; K K Stanley
Journal:  Nucleic Acids Res       Date:  1987-12-10       Impact factor: 16.971

6.  Functional heterogeneity among herpes simplex virus-specific human CD4+ T cells.

Authors:  M Yasukawa; A Inatsuki; T Horiuchi; Y Kobayashi
Journal:  J Immunol       Date:  1991-02-15       Impact factor: 5.422

7.  Herpes simplex virus (HSV)-specific proliferative and cytotoxic T-cell responses in humans immunized with an HSV type 2 glycoprotein subunit vaccine.

Authors:  J M Zarling; P A Moran; L Brewer; R Ashley; L Corey
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

8.  Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection.

Authors:  A Langenberg; J Benedetti; J Jenkins; R Ashley; C Winter; L Corey
Journal:  Ann Intern Med       Date:  1989-06-01       Impact factor: 25.391

9.  Helper activity in antigen-specific antibody production mediated by CD4+ human cytotoxic T cell clones directed against herpes simplex virus.

Authors:  M Yasukawa; A Inatsuki; Y Kobayashi
Journal:  J Immunol       Date:  1988-05-15       Impact factor: 5.422

10.  Anti-CD8 impairs clearance of herpes simplex virus from the nervous system: implications for the fate of virally infected neurons.

Authors:  A Simmons; D C Tscharke
Journal:  J Exp Med       Date:  1992-05-01       Impact factor: 14.307
View more
  20 in total

1.  A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.

Authors:  Sita Awasthi; Gregory G Mahairas; Carolyn E Shaw; Meei-Li Huang; David M Koelle; Christine Posavad; Lawrence Corey; Harvey M Friedman
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

2.  Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine.

Authors:  Lichen Jing; Jürgen Haas; Tiana M Chong; Joseph J Bruckner; Greg C Dann; Lichun Dong; Joshua O Marshak; Christopher L McClurkan; Tori N Yamamoto; Susanne M Bailer; Kerry J Laing; Anna Wald; Georges M G M Verjans; David M Koelle
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

3.  Identification of novel Mycobacterium tuberculosis CD4 T-cell antigens via high throughput proteome screening.

Authors:  Kaustuv Nayak; Lichen Jing; Ronnie M Russell; D Huw Davies; Gary Hermanson; Douglas M Molina; Xiaowu Liang; David R Sherman; William W Kwok; Junbao Yang; John Kenneth; Syed F Ahamed; Anmol Chandele; Kaja Murali-Krishna; David M Koelle
Journal:  Tuberculosis (Edinb)       Date:  2015-03-27       Impact factor: 3.131

4.  Laser Adjuvant-Assisted Peptide Vaccine Promotes Skin Mobilization of Dendritic Cells and Enhances Protective CD8+ TEM and TRM Cell Responses against Herpesvirus Infection and Disease.

Authors:  Patricia P Lopes; George Todorov; Thanh T Pham; Anthony B Nesburn; Elmostafa Bahraoui; Lbachir BenMohamed
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

5.  Homing in on the cellular immune response to HSV-2 in humans.

Authors:  David M Koelle; Julio C Gonzalez; Andrew S Johnson
Journal:  Am J Reprod Immunol       Date:  2005-04       Impact factor: 3.886

6.  Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system.

Authors:  Ashok Cattamanchi; Christine M Posavad; Anna Wald; Yaela Baine; Jennifer Moses; Terry J Higgins; Richard Ginsberg; Richard Ciccarelli; Lawrence Corey; David M Koelle
Journal:  Clin Vaccine Immunol       Date:  2008-09-10

7.  Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection.

Authors:  William J Muller; Lichun Dong; Adrian Vilalta; Benjamin Byrd; Kai M Wilhelm; Christopher L McClurkan; Michal Margalith; Chao Liu; David Kaslow; John Sidney; Alessandro Sette; David M Koelle
Journal:  J Gen Virol       Date:  2009-03-04       Impact factor: 3.891

8.  An extremely diverse CD4 response to vaccinia virus in humans is revealed by proteome-wide T-cell profiling.

Authors:  Lichen Jing; D Huw Davies; Tiana M Chong; Sookhee Chun; Christopher L McClurkan; Jay Huang; Brian T Story; Douglas M Molina; Siddiqua Hirst; Philip L Felgner; David M Koelle
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

9.  Development of effective vaccines for old mice in a tumor model.

Authors:  David N Posnett; Manuel E Engelhorn; Yun Lin; Taha Merghoub; Fei Duan; Jedd D Wolchok; Alan N Houghton
Journal:  Vaccine       Date:  2008-12-25       Impact factor: 3.641

10.  A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge.

Authors:  X Zhang; A A Chentoufi; G Dasgupta; A B Nesburn; M Wu; X Zhu; D Carpenter; S L Wechsler; S You; L BenMohamed
Journal:  Mucosal Immunol       Date:  2008-12-24       Impact factor: 7.313
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.